Big drugmakers Pfizer, Johnson & Johnson and Amgen have submitted data-mining analyses of electronic medical records to the Food and Drug Administration to help expedite the approval of new or improved medicines, the Wall Street Journal reports.
Why it matters: So far, parsing patient data instead of carrying out long clinical trials has cut costs and shortened drug-development times for breast cancer, bladder cancer and leukemia drugs.
Details: Companies take hospital and doctor files for cases where patients already took a drug during routine care and then analyze the changes in health data to test side effects.
Yes, but: Relying on health records, which often contain errors, doesn't produce the same level of scientific scrutiny as clinical trials.
